Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel
نویسندگان
چکیده
Dear Editor, About 20-40% of patients who undergo primary therapy for early-stage prostate cancer, experience biochemical relapse of which 30-70% develop metastatic disease within 10 years1 and the majority will become resistant to castration (CRPC). Since 2004, docetaxel has been the first-line cytotoxic treatment in treating metastatic CRPC. However, many mCRPC patients eventually become resistant to docetaxel, for whom available treatment options are limited.2 Cabazitaxel, a next-generation taxane, is the first agent to demonstrate improved survival post-docetaxel in mCRPC patients.3-5 In 2007, a 62-year-old patient presented to our clinic with a PSA=6.5 ng/ml. He refused a biopsy, and returned in August 2009 with PSA=19 ng/ml. Prostate biopsy was done in September 2009, followed by radical prostatectomy. The pathology report came back as prostate adenocarcinoma with Gleason 3+4, extensive PNI, and involvement of both lobes as well as the right seminal vesicle (pT3). Iliac lymph nodes were free of tumor. After the surgery, PSA reduced to 0.1 ng/ml and he was planned to receive radiation therapy to the prostate bed followed by monthly decapeptyl. In November 2011, while still on androgen deprivation therapy with PSA=0.05 ng/ml, he developed dyspnea and hemoptysis. A chest CT scan revealed several masses in both lungs and metastasis was proved by biopsy (figure 1).
منابع مشابه
Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel
متن کامل
Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient
We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific antigen doubling time was found to be a good response predictor in the patient.
متن کاملSafety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
Prostate cancer (PC) is one of the most common cancers and is a leading cause of death. Its initial growth is dependent on androgens; most patients show an initial response to hormonal therapy but will experience disease progression when PC becomes resistant to castration. In 2004, two key randomized controlled trials demonstrated a benefit for docetaxel-based regimens in the treatment of men w...
متن کاملDutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
BACKGROUND The treatment of metastatic castration-resistant prostate cancer has changed with the introduction of radium-223, cabazitaxel, abiraterone and enzalutamide. To assess value for money, their cost effectiveness in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel from the Dutch societal perspective was investigated. METHODS A cost-effecti...
متن کاملCastration-resistant prostate cancer: systemic therapy in 2012
Prostate cancer is the most common non-cutaneous neoplasm in the male population worldwide. It is typically diagnosed in its early stages, and the disease exhibits a relatively indolent course in most patients. Despite the curability of localized disease with prostatectomy and radiation therapy, some patients develop metastatic disease and die. Although androgen deprivation is present in the ma...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 40 شماره
صفحات -
تاریخ انتشار 2015